Vyvgart (Efgartigimod) Market Size & Growth Forecast 2027–2036, By Segments (Indication, Route of Administration), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Vyvgart (Efgartigimod) Market size was over USD 2.74 billion in 2026 and is likely to grow at a 14.14% CAGR between 2027 and 2036, exceeding USD 10.28 billion by 2036. The industry revenue for 2027 is calculated at USD 3.08 billion.
Get more details on this report
Request Free Sample ReportVyvgart (Efgartigimod) Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 87.73% of revenue, supported by established healthcare infrastructure, specialized treatment centers, access to specialist consultations, and demand for innovative autoimmune therapies.
- Asia Pacific is expected to grow fastest as healthcare infrastructure improves, specialist care expands, and greater awareness of autoimmune diseases supports access to advanced treatment options.
Segment Momentum
- Generalized myasthenia gravis accounted for 95.75% of the market in 2026, reflecting its central role in efgartigimod use. Demand is supported by the need for targeted treatment options and individualized management of this chronic autoimmune disorder.
- Subcutaneous injection is the fastest-growing administration route, supported by its potential to improve treatment convenience and flexibility. Compared with prolonged infusion visits, it may better accommodate patients' daily commitments and expand administration options.
Market Expansion Drivers
- Increasing Adoption of Vyvgart (Efgartigimod) for Autoimmune Disorders.
- Expansion of Clinical Trials and Regulatory Approvals.
- Advancements in Monoclonal Antibody Therapy Technology.
Leading Market Participants
- Key companies in the vyvgart (efgartigimod) market include argenx (Netherlands), UCB (Belgium), Roche (Switzerland), Novartis (Switzerland), AstraZeneca (UK), Sanofi (France), Pfizer (USA), AbbVie (USA), Johnson & Johnson (USA), Bristol Myers Squibb (USA).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 2.74 billion
- 2027 Estimated Market Size: USD 3.08 billion
- Projected Market Size: USD 10.28 billion by 2036
- Growth Forecast: 14.14% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Indication (Generalized Myasthenia Gravis (gMG)) | Route of Administration (Intravenous (IV) Infusion)
- Emerging Opportunity Segment: Indication (Generalized Myasthenia Gravis (gMG)) | Route of Administration (Subcutaneous (SC) Injection)
Market Growth Drivers and Industry Trends
Increasing Adoption of Vyvgart (Efgartigimod) for Autoimmune Disorders
Increasing adoption of efgartigimod-based therapy for autoimmune disorders is supported by growing recognition of targeted treatment approaches that address disease mechanisms associated with pathogenic immunoglobulins. The therapy's mechanism of reducing circulating IgG antibodies provides a differentiated approach to managing certain autoimmune conditions, particularly where conventional treatments may not provide adequate disease control. Greater physician awareness, expanding treatment experience, and efforts to improve patient access are supporting its integration into autoimmune disease management.
Expansion of Clinical Trials and Regulatory Approvals
Expansion of clinical trials and regulatory approvals is broadening the potential application of efgartigimod across autoimmune disorders. Ongoing clinical research can generate additional evidence regarding efficacy, safety, dosing approaches, and patient populations, while regulatory developments may expand access to the therapy across new indications and geographic markets. A broader clinical evidence base can also improve physician confidence and support the incorporation of targeted immunomodulatory treatments into evolving therapeutic strategies.
Advancements in Monoclonal Antibody Therapy Technology
Advancements in monoclonal antibody therapy technology are supporting the development of more targeted approaches to autoimmune disease management. Improvements in antibody engineering, molecular design, formulation, and delivery technologies can enhance therapeutic specificity and enable more effective modulation of immune pathways. Continued progress in biologic therapies is also expanding opportunities to develop treatments that selectively influence disease-related immune mechanisms while supporting more personalized approaches to the management of chronic autoimmune disorders.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing Adoption of Vyvgart (Efgartigimod) for Autoimmune Disorders | 5.5% | Short term (≤ 2 yrs) | North America; Europe | High | Fast |
| Expansion of Clinical Trials and Regulatory Approvals | 5% | Medium term (2–5 yrs) | Asia Pacific; North America | High | Moderate |
| Advancements in Monoclonal Antibody Therapy Technology | 3.6% | Long term (5+ yrs) | Europe; Asia Pacific | Low | Moderate |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America dominated the global vyvgart (efgartigimod) market, accounting for the largest revenue share of 87.73%. The region’s established healthcare infrastructure, access to specialized treatment centers, and strong emphasis on innovative therapies for autoimmune diseases are important factors supporting market dominance. Increasing awareness of targeted treatment approaches and the growing need for therapies that address underlying immune system mechanisms are contributing to demand. Furthermore, established clinical care networks and access to specialist consultations support the identification and management of patients who may benefit from advanced treatments. The region’s well-developed biopharmaceutical ecosystem and emphasis on expanding treatment options for chronic autoimmune conditions further reinforce the market outlook.
Asia Pacific (Fastest-Growing Region)
The Asia Pacific vyvgart (efgartigimod) market is anticipated to register the fastest growth, supported by improving healthcare infrastructure, expanding access to specialist care, and growing awareness of autoimmune diseases. Increasing investments in healthcare services and the gradual development of advanced diagnostic and treatment capabilities are creating opportunities for innovative therapies across the region. Furthermore, improvements in disease recognition and patient referral pathways may support the identification of individuals requiring specialized treatment. The expansion of healthcare access and the growing focus on improving outcomes for patients with complex immune-mediated conditions are expected to contribute to market growth.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Established Specialty AdoptionThe U.S. VYVGART market is supported by established clinical familiarity and specialty-care infrastructure for autoimmune disease management. Near-term priorities include appropriate patient identification, treatment sequencing, access and reimbursement management, and broader integration of efgartigimod into neurologist-led care pathways.
Germany 🇩🇪
Specialist Treatment AccessGermany’s VYVGART market is shaped by specialist prescribing, reimbursement considerations, and structured management of autoimmune neuromuscular conditions. Commercial priorities include evidence generation, physician awareness, patient selection, and efficient integration of efgartigimod into established specialty treatment pathways.
Japan 🇯🇵
Regulatory-Driven ExpansionJapan’s VYVGART market depends heavily on specialist adoption and alignment with local treatment practices for autoimmune disorders. Priorities include clinician education, appropriate patient identification, evidence supporting treatment positioning, and streamlined access through specialist healthcare settings and reimbursement mechanisms.
South Korea 🇰🇷
Specialty Immunology UptakeSouth Korea’s VYVGART market is centered on specialist management of antibody-mediated autoimmune disease and access through established hospital channels. Key priorities include reimbursement accessibility, physician familiarity, patient identification, and evidence demonstrating the practical role of efgartigimod within treatment pathways.
France 🇫🇷
Hospital-Based Treatment IntegrationFrance’s VYVGART market is influenced by specialist and hospital-based treatment pathways for eligible autoimmune patients. Commercial priorities include evidence-led positioning, reimbursement access, physician education, and incorporation of efgartigimod into multidisciplinary approaches for patients requiring targeted immunomodulation.
Italy 🇮🇹
Specialist Care AdoptionItaly’s VYVGART market is closely linked to specialist diagnosis and management of eligible autoimmune conditions within hospital-centered care. Priorities include improving patient identification, supporting neurologist familiarity, navigating reimbursement pathways, and establishing practical treatment protocols for efgartigimod use.
Vyvgart (Efgartigimod) Market Share (%), by Indication, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportIndication Segment Analysis: Generalized Myasthenia Gravis (gMG) (Largest & Fastest-Growing Segment)
Generalized myasthenia gravis (gMG) accounts for 95.75% share of the vyvgart (efgartigimod) market in 2026, reflecting its central role in the current use of efgartigimod and the substantial unmet need for targeted treatment options among patients with this chronic autoimmune disorder. The condition can cause fluctuating muscle weakness that affects daily activities and may require ongoing disease management, supporting demand for therapies that address the underlying immune mechanism. Efgartigimod’s targeted action on the neonatal fc receptor helps reduce circulating immunoglobulin G, offering a treatment approach distinct from conventional broad immunosuppression. Growing clinical familiarity, increased recognition of disease burden, and the need for treatment options that can be incorporated into individualized care plans are reinforcing the segment’s leading position. Continued adoption across specialist care settings and interest in targeted therapies are also expected to support its growth.
Route of Administration Segment Analysis: Intravenous (IV) Infusion (Largest Segment) vs Subcutaneous (SC) Injection (Fastest-Growing Segment)
Intravenous (IV) infusion represents the largest route of administration segment, accounting for a 93.88% 2026 vyvgart (efgartigimod) market share, supported by its established role in delivering efgartigimod treatment under clinical supervision. Infusion-based administration is familiar to neuromuscular specialists and healthcare teams, enabling patients to receive therapy within structured care pathways where dosing, monitoring, and response can be managed. Existing clinical experience and infrastructure at hospitals and infusion centers further contribute to its substantial use. Meanwhile, subcutaneous (SC) injection is expected to grow at the fastest pace as it offers the potential for greater convenience and flexibility in treatment delivery. The option may reduce reliance on prolonged infusion visits and better accommodate patients seeking care that fits around work, family, and other daily commitments. As clinicians and patients increasingly consider administration preferences alongside treatment outcomes, subcutaneous delivery is positioned to gain broader acceptance.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Indication | Generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Others | Generalized Myasthenia Gravis (gMG) | Generalized Myasthenia Gravis (gMG) |
| Route of Administration | Intravenous (IV) Infusion, Subcutaneous (SC) Injection, Prefilled Syringe | Intravenous (IV) Infusion | Subcutaneous (SC) Injection |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Analyst Perspective:
Expanding Vyvgart into additional IgG-mediated autoimmune indications broadens its addressable market, though commercial momentum relies on establishing clear clinical superiority over competing complement inhibitors and FcRn targeted therapies. Offering subcutaneous injections alongside intravenous options improves patient convenience and aligns better with varied healthcare delivery settings. Nevertheless, navigating complex payer coverage, stringent prior authorization hurdles, and reimbursement frameworks remains essential to securing broad patient access.
Major players in the vyvgart (efgartigimod) market:
- argenx (Netherlands)
- UCB (Belgium)
- Roche (Switzerland)
- Novartis (Switzerland)
- AstraZeneca (UK)
- Sanofi (France)
- Pfizer (USA)
- AbbVie (USA)
- Johnson & Johnson (USA)
- Bristol Myers Squibb (USA)
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| argenx (Netherlands) | |||||||
| UCB (Belgium) | |||||||
| Roche (Switzerland) | |||||||
| Novartis (Switzerland) | |||||||
| AstraZeneca (UK) | |||||||
| Sanofi (France) | |||||||
| Pfizer (USA) | |||||||
| AbbVie (USA) | |||||||
| Johnson & Johnson (USA) | |||||||
| Bristol Myers Squibb (USA) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| argenx | August 2026 | argenx announced positive Phase 3 ALKIVIA trial results for Vyvgart in autoimmune myositis, successfully meeting the primary endpoint for the subcutaneous FcRn inhibitor. The trial demonstrated meaningful improvements in disease activity across patient subsets, including immune-mediated necrotizing myopathy, expanding the therapy's clinical potential beyond established indications. |
| argenx | May 2026 | The U.S. FDA approved a label expansion for Vyvgart and Vyvgart Hytrulo in adult patients with generalized myasthenia gravis. This regulatory decision broadens the eligible patient population for both formulations within the United States, supporting deeper commercial penetration in its primary therapeutic indication. |
| argenx | December 2025 | argenx secured UK MHRA approval for a new indication of Vyvgart via the reliance review process. The authorization expands the therapeutic footprint and commercial reach of the FcRn inhibitor for autoimmune conditions within the United Kingdom market. |
| argenx | August 2025 | argenx reported positive Phase 3 trial results for Vyvgart in seronegative generalized myasthenia gravis, initiating preparations for a regulatory filing to expand its label. Representing roughly 20% of the patient population, this demographic expansion significantly increases the addressable market for the therapy. |
| argenx | June 2025 | The European Commission approved subcutaneous Vyvgart as a monotherapy for adults with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy. This authorization extends the commercial availability of efgartigimod into a critical rare peripheral nerve disease across European markets. |
| argenx | April 2025 | argenx received U.S. FDA approval for a prefilled syringe enabling self-injection of Vyvgart Hytrulo for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy patients. The delivery innovation enhances patient convenience, reduces dependence on clinic-based infusions, and supports improved long-term treatment adherence. |
| Zai Lab Limited | November 2024 | China's National Medical Products Administration approved Zai Lab and argenx's supplemental Biologics License Application for Vyvgart Hytrulo in chronic inflammatory demyelinating polyneuropathy. As the first approved CIDP therapy in China utilizing a rapid subcutaneous injection, the milestone establishes strong market entry and competitive positioning in Asia's rare disease sector. |
| argenx | June 2024 | The U.S. FDA approved Vyvgart Hytrulo for chronic inflammatory demyelinating polyneuropathy, establishing the therapy's second major indication in the United States. The approval successfully transitions efgartigimod from generalized myasthenia gravis into a broader spectrum of debilitating peripheral nervous system disorders. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Vyvgart (Efgartigimod) Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Line of Therapy | First-Line Therapy, Second-Line Therapy, Third-Line & Later Therapy |
| Treatment Setting | Hospitals & Specialty Centers, Outpatient Clinics, Physician Offices, Home-Based Care |
Vyvgart (Efgartigimod) Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Reimbursement and Market Access Pathways |
|
| Treatment Sequencing and Physician Adoption |
|
| FcRn Therapy Competitive Positioning |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
How big is the vyvgart (efgartigimod) market?
How much is the vyvgart (efgartigimod) industry expected to grow by 2036?
How are clinical development and regulatory expansion influencing adoption of efgartigimod?
How are advances in monoclonal antibody technology supporting demand for targeted autoimmune therapies?
Why does generalized myasthenia gravis dominate the Vyvgart market?
How is subcutaneous administration changing demand in the Vyvgart market?
Why does North America lead the Vyvgart (Efgartigimod) market?
What is driving Vyvgart (Efgartigimod) market growth in Asia Pacific?
Who are the major participants shaping the vyvgart (efgartigimod) landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook